David M. Kaufman

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/6c9bb600-a530-11ec-9e70-29a1c531b228.jpeg

First Name

David

Last Name

Kaufman

NPI

1124103817

Faculty ID

5569

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="font-family: Arial;">David Myland Kaufman, Professor of Neurology and Psychiatry and Behavioral Sciences, was graduated from the medical school of the University of Chicago and completed training in internal medicine and then neurology at Montefiore Medical Center / Albert Einstein College of Medicine (AECOM) hospitals.&nbsp; During his residency, Dr. Kaufman originated the nation-wide course, which he still directs, Clinical Neurology for Psychiatrists.&nbsp; More than 25,500 psychiatry residents and attendings have attended the course, which has served as the basis for his classic textbook, <em>Clinical Neurology for Psychiatrists</em>, (Elsevier) currently in its eighth edition and available in Italian, Japanese, and Spanish translations. He is also a co-editor of <em>Child and Adolescent Neurology for Psychiatrists</em> (Lippincott).</span></p>
<p><span style="font-family: Arial;">Dr. Kaufman has also been a visiting professor at Ben Gurion University, Yale University, Pritzger / University of Chicago, and other American medical schools, and U.S. Naval Medical Centers, as well as a frequent lecturer at AECOM. He is a member of medical school's Leo M. Davidoff Society for excellence in teaching.&nbsp;</span></p>
<p><span style="font-family: Arial;">In addition to his educational role at AECOM hospitals, Dr. Kaufman in partnership with Dr. Michael Swerdlow founded the quintessential neurology faculty practice&nbsp; K&amp;S&nbsp; at Montefiore Hospital. K&amp;S is the largest and longest surviving faculty practice in the institution. Drs. Kaufman and Swerdlow also give neurology consultation and attending rounds and supervise neurology clinics at Montefiore. In the clinics and faculty practice, Dr. Kaufman concentrates on the neurologic aspects of psychiatric illness and movement disorders. He works closely with the psychiatrists and, for botulinum treatment of certain dystonias, the neuromuscular group. Dr. Kaufman is the 2007 recipient of Montefiore's Staff and Alumni award for outstanding service.</span></p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

In addition to his educational role at AECOM and its hospitals, Dr. Kaufman in partnership with Dr. Michael Swerdlow founded the quintessential neurology faculty practice K&amp;S at Montefiore Hospital. K&amp;S is the largest and longest-surviving faculty practice in the institution. Drs. Kaufman and Swerdlow also give neurology consultations and attend rounds and supervise neurology clinics at Montefiore. In the clinics and faculty practice, Dr. Kaufman concentrates on the neurologic aspects of psychiatric illness and movement disorders. He works closely with psychiatrists and, for botulinum treatment of certain dystonia, the neuromuscular group.

Research Focus

From his research interests, Dr. Kaufman has published clinical studies of central nervous system infections, heroin overdose-induced pulmonary edema, Covid&rsquo;s effect on Parkinson's disease patients, and other topics. He concentrates on teaching medical students in their neuroscience courses, psychiatry and neurology residents, and psychiatrists preparing for their Board examinations.

Elsevier Profile

Selected Publications

<p>Kaufman DM, Geyer HL, Milstein MM: "Kaufman's Clinical Neurology for Psychiatrists," Elsevier, 8th Edition, 2017</p>
<p>Kaufman DM, Smuckler DJ: Neurologic Disease (in) Blumenfeld M, Strain JJ, "Psychosomatics," Lippincott Williams &amp; Wilkins, 2006</p>

EMR ID

3338

Biography

<p>David Kaufman, MD, an attending physician and Professor of Neurology and of Psychiatry and Behavioral Sciences at Montefiore Einstein, concentrates on the neurologic aspects of psychiatric illness and movement disorders. He provides neurology consultations for in-patients and out-patients, serves as the attending on consultation and ward rounds, and supervises neurology clinics at Montefiore Einstein. He works closely with psychiatrists and, for botulinum treatment of certain dystopias, the neuromuscular group.</p><p>After earning his Bachelor of Arts from the University of Rochester in 1964, Dr. Kaufman earned his Doctor of Medicine degree from the University of Chicago School of Medicine in 1968. He pursued his postdoctoral training at Montefiore, completing his internal medicine internship and residency in 1971. In 1975, he completed the four-year neurology residency at Albert Einstein College of Medicine hospitals. He has been a steadfast member of Montefiore and Einstein communities ever since.</p><p>From his research interests, Dr. Kaufman has published clinical studies of central nervous system infections, heroin overdose-induced pulmonary edema, COVID&rsquo;s effect on Parkinson disease patients, and other topics. He has been a member of editorial boards for Internal Medicine Bulletin and Medical Meetings: Pearls &amp; Perspectives, and a consultant and reviewer for numerous medical journals. He teaches medical students in their neuroscience course, psychiatry and neurology residents, and psychiatrists preparing for their Board examinations. He has been a Visiting Professor at Ben Gurion University, Yale University, Pritzker/University of Chicago, and other American medical schools, and at U.S. Naval Medical Centers, as well as a frequent lecturer at the Albert Einstein College of Medicine.</p><p>Dr. Kaufman innovated the long-standing, annual, national course, Clinical Neurology and Psychiatry for Psychiatrists, developed a noteworthy neuropsychiatry seminar and authored the book, <em>Kaufman&rsquo;s Clinical Neurology for Psychiatrists</em>, now in its 9th edition.</p><p>Dr. Kaufman is board certified in Internal Medicine, and Psychiatry and Neurology. He is a fellow of the American Academy of Neurology and the American College of Physicians. He is also a member of the American Neuropsychiatric Association and the Movement Disorder Society. A devoted educator, Dr. Kaufman has received many accolades for his excellence in medical teaching, including induction into the Leo M. Davidoff Society in 1993, the American Academy of Neurology award in 2001 and the Montefiore Staff and Alumni Award in 2007.</p>

Is Open Scheduling

Off

Steven Herskovitz

https://assets.montefioreeinstein.org/profiles/images/physphoto/Herskovitz_Steven_MD_420x504.jpg

First Name

Steven

Last Name

Herskovitz

NPI

1588749808

Faculty ID

5668

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Herskovitz is Professor of Clinical Neurology and Director of the EMG Lab / Neuromuscular division. He earned his medical degree from Cornell University Medical Center in 1980. He completed residencies in both Internal Medicine and Neurology, followed by a Fellowship in Electromyography/Neuromuscular Disorders,&nbsp;all at the Albert Einstein College of Medicine. He is a diplomate of the ABIM, ABPN, ABEM, and ABPN-AQNM. His clinical research interests include the peripheral neuropathies, entrapment neuropathies and peripheral&nbsp;neurotoxicology. He has published on various aspects of carpal tunnel syndrome including electrophysiologic diagnosis, treatment and autonomic features, clinical features of a variety of peripheral neuropathies, and the neurotoxicology of pharmaceutical and industrial agents. He is author of: <em>Herskovitz S, Scelsa S, Schaumburg HH. Peripheral Neuropathies in Clinical Practice. Contemporary Neurology Series. Oxford University Press. New York. 2010</em>. Two positions are available yearly in the clinical neurophysiology /EMG fellowship program.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Herskovitz focuses on the clinical and neurodiagnostic (EMG; neuromuscular ultrasound) evaluation of neuromuscular disorders.

Research Focus

Dr. Herskovitz's research is focused on the clinical and neurodiagnostic assessment of neuropathies.

Elsevier Profile

Selected Publications

<p><strong>Bibliography</strong><br /><br /><strong>A. Original Communications in Reviewed Journals:</strong></p>
<p>1. Lipton RB, Krupp L, Horoupian D, Herskovitz S, Arezzo JC, Kurtzberg D. Progressive multifocal leukoencephalopathy of the posterior fossa in an AIDS patient: Clinical, radiographic and evoked potential findings. European Neurology. 28:258?261,1988.</p>
<p>2. Herskovitz S, Lipton RB, Lantos G. NeuroBehcet's disease: CT and clinical correlates. Neurology. 38:1714?1720, 1988.</p>
<p>3. Herskovitz S, Siegel SE, Schneider AT, Nelson SJ, Goodrich JT, Lantos G. Spinal cord toxoplasmosis in AIDS. Neurology. 39:1552?1553, 1989.</p>
<p>4. Loh F, Herskovitz S, Berger AR, Swerdlow M. Brachial plexopathy associated with interleukin 2 therapy. Neurology. 42:462?463, 1992.</p>
<p>5. Newman LC, Herskovitz S, Lipton RB, Solomon S. Chronic paroxysmal headache: Two cases with cerebrovascular disease. Headache 32: 75?76, 1992.</p>
<p>6. Gonzales GR, Herskovitz S, Rosenblum M, et al. Dejerine Roussy syndrome caused by CNS toxoplasmosis in patients with AIDS. Neurology 42: 1107?1109, 1992.</p>
<p>7. Herskovitz S, Gordon M, Strauch B. Shiatsu massage induced injury of the median recurrent motor branch. Muscle &amp; Nerve 15 (10): 1215, 1992.</p>
<p>8. Herskovitz S, Loh F, Berger AR, Kucherov M. Erythromelalgia: Association with hereditary sensory neuropathy and response to amitriptyline. Neurology 43: 621?622, 1993.</p>
<p>9. Herskovitz S, Bieri P, Berger AR. Depressor septi nasi myokymia. Muscle &amp; Nerve 17: 116, 1994.</p>
<p>10. Strominger MB, Slamovits TL, Herskovitz S, Lipton RB. Transient worsening of optic neuropathy as a sequela of the Jarisch?Herxheimer reaction in the treatment of Lyme disease. J Neuro Ophthalmol 14(2): 77?80, 1994.</p>
<p>11. Scelsa SN,, Lipton RB, Sanders H, Herskovitz S. Headache characteristics in hospitalized patients with Lyme disease. Headache 35 (3): 125-130, 1995.</p>
<p>12. Berger AR, Herskovitz S, Kaplan J. Late motor involvement in cases presenting as chronic sensory demyelinating polyneuropathy. Muscle &amp; Nerve 18: 440-444, 1995.</p>
<p>13. Herskovitz S, Berger AR, Lipton, RB. Low dose, short-term oral prednisone in the treatment of carpal tunnel syndrome. Neurology 45: 1923-1925, 1995.</p>
<p>14. Berger AR, Herskovitz, S, Scelsa SN. Restoration of IVIg efficacy by plasma exchange in CIDP. Neurology 45: 1628-1629, 1995.</p>
<p>15. Oware A, Herskovitz S, Berger AR. Long thoracic nerve palsy associated with chiropractic manipulation. Neurology 18:1351, 1995.</p>
<p>16. Berger AR, Swerdlow M, Herskovitz S. Myasthenia gravis presenting with uncontrollable flatulence and urinary/fecal incontinence. Muscle &amp; Nerve 19: 113-114, 1996.</p>
<p>17. Scelsa SN, Berger AR, Herskovitz S. The diagnostic utility of F waves in L5/S1 radiculopathy. Muscle &amp; Nerve 18: 1496, 1995.</p>
<p>18. Scelsa SN, Herskovitz S, Berger AR. A predominantly motor polyradiculopathy of Lyme disease. Muscle &amp; Nerve 19: 780-783, 1996.</p>
<p>19. Scelsa SN, Herskovitz S, Bieri P, Berger AR. Median mixed and sensory conduction studies in carpal tunnel syndrome. Electroencephalography and Clinical Neurophysiology 109: 268-273, 1998</p>
<p>20. Scelsa SN, Herskovitz S, Reichler B. Treatment of Mononeuropathy Multiplex in Hepatitis C Virus and Cryoglobulinemia. Muscle &amp; Nerve 21: 1526-1529, 1998.</p>
<p>21. Scelsa SN, Herskovitz S. Miller Fisher syndrome: axonal, demyelinating or both? Electromyogr. Clin. Neurophysiol. 40: 497-502, 2000.</p>
<p>22. Manfredi PL, Herskovitz S, Folli F, Pigazzi A, Swerdlow ML. Spinal epidural abscess: treatment options. Eur Neurol 40:58-60, 1998.</p>
<p>23. Berger AR, Schaumburg HH, Freeman K, Gourevitch MN, Herskovitz S, Arezzo JC. Prevalence of peripheral neuropathy in injection drug users. Neurology 1999; 53: 592-597</p>
<p>24. Verghese J, Galanopoulou AS, Herskovitz S. Autonomic dysfunction in idiopathic carpal tunnel syndrome. Muscle &amp; Nerve 23: 1209-1213, 2000.</p>
<p>25. Scelsa S, Berger A, Herskovitz S. Electrophysiologic correlates of L5/S1 radiculopathy. Electromyogr. clin. Neurophysiol 2001, 41, 145-151.</p>
<p>26. Verghese J, Bieri PL, Gellido C, Schaumburg HH, Herskovitz S. Peripheral neuropathy in young-old and old-old patients. Muscle &amp; Nerve 24: 1476-1481, 2001.</p>
<p>27. Scelsa S, Ghali V, Herskovitz S, et al. Blood &atilde;&auml; T cells, Campylobacter jejuni, and GM1 titers in Guillain Barre syndrome. Muscle &amp; Nerve 30: 423-432, 2004.</p>
<p>28. Geyer H, Schaumburg HH, Herskovitz S. Methyl bromide intoxication causes reversible, symmetric, brainstem and cerebellar MRI lesions. Neurology 2005; 64:1279-1281.</p>
<p>29. Herskovitz S, Song H, Cozien D, Scelsa S. Sensory symptoms in acquired neuromyotonia. Neurology 2005;65:1330-1331.</p>
<p>30. Schaumburg HH, Herskovitz S, Cassano V. Occupational manganese neurotoxicity provoked by hepatitis C. Neurology 2006;67:322-3.</p>
<p>31. Blumenthal S, Herskovitz S, Verghese J. Carpal tunnel syndrome in older adults. Muscle &amp; Nerve 2006;34:78-83.</p>
<p>32. Schaumburg HH, Herskovitz S. Is acquired copper deficiency myeloneuropathy from denture cream use a clue to clioquinol-induced subacute myelo-optic neuropathy (SMON)? Neurology 2008; 71 (9):622.</p>
<p>33. Robbins MS, Roth S, Swerdlow ML, Bieri P, Herskovitz S. Optic neuritis and palatal dysarthria as presenting features of post-infectious GQ1b antibody syndrome. Clin Neurol Neurosurg 2009;111:465-466.</p>
<p>34. Issa SS, Herskovitz S, Lipton RB. Acquired neuromyotonia as a paraneoplastic manifestation of ovarian cancer. Neurology 2011;76:101-103 .</p>
<p><strong>B. Books, Chapters in Books, Editorials and Review Articles:</strong></p>
<p>1. Contributing author: Pousada, L, Osborn HH. Emergency Medicine for the House Officer. Williams and Wilkins, 1986. (chapters on headache and CPR).</p>
<p>2. Contributing author: Schaumburg HH, Berger AR, Thomas PK. Disorders of Peripheral Nerves, 2nd edition, F.A. Davis, 1992.</p>
<p>3. Berger AR, Herskovitz S. Cumulative trauma disorders and occupational nerve disease. In: Rosenberg, N ed. Occupational and Environmental Neurology. Butterworth-Heinemann, Boston, 1995.</p>
<p>4. Assistant Editor: Spencer PS, Schaumburg HH, Ludolph AC. Experimental and Clinical Neurotoxicology, 2nd edition. Oxford University Press, 2000.</p>
<p>5. Schaumburg HH, Herskovitz S. The Weak Child &ndash; A Cautionary Tale. N Engl J Med 2000 (editorial); 342, 127-129.</p>
<p>6. Herskovitz, S. Toxic neuropathies &ndash; Amiodarone, Gold, Perhexilene, Misonidazole. In Medlink Neurology (www.medlink.com), 2001/2002/2003/2004/2005/2006.</p>
<p>7. Herskovitz S, Schaumburg HH. Neuropathy due to drugs. In: Dyck PJ, Thomas PK, editors: Peripheral Neuropathy, 4th edition, 2005.</p>
<p>8. Herskovitz S, Scelsa S, Schaumburg HH. Peripheral Neuropathies in Clinical Practice.&nbsp;Contemporary Neurology Series. Oxford University Press. New York. 2010.</p>

EMR ID

3322

Biography

<p>Steven Herskovitz, MD, is Director, Neuromuscular Medicine and Director, Electromyography (EMG) Lab at Montefiore. He is also Professor of Neurology at our Albert Einstein College of Medicine. Dr. Herskovitz&rsquo;s clinical focus is on the evaluation and management of all neuromuscular disorders, with a particular interest in electrodiagnostic and neuromuscular ultrasound assessment.</p><p>In 1976, Dr. Herskovitz received his Bachelor of Science in biology at the State University of New York at Stony Brook. He then attended Cornell University Medical College, where he received his Doctor of Medicine in 1980. From 1980 to 1987, Dr. Herskovitz completed his postgraduate training at Montefiore. During this time, he spent his first year as a medical intern and next two years as a medical resident. In 1983, he began a three-year neurology residency, becoming Chief Resident in the final year. He ended his postgraduate training with a fellowship in Electromyography and Neuromuscular Diseases.</p><p>Expanding on his clinical focus, Dr. Herskovitz&rsquo;s research centers on clinical, electrodiagnostic and neuromuscular ultrasound assessment of neuropathies. His work has been published in many peer-reviewed journals, books, review articles and abstracts.</p><p>Dr. Herskovitz is board certified by the American Board of Internal Medicine, the American Board of Psychiatry and Neurology, including Added Qualification in Neuromuscular Medicine, and the American Board of Electrodiagnostic Medicine. He is a member of the American Academy of Neurology and the American Association of Neuromuscular and Electrodiagnostic Medicine.</p>

Is Open Scheduling

Off

Sheryl R. Haut

https://assets.montefioreeinstein.org/profiles/images/physphoto/Haut_Sheryl_MD_420x504.jpg

First Name

Sheryl

Last Name

Haut

NPI

1679658991

Faculty ID

5312

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Sheryl Haut is Director of the Adult Epilepsy Program and Chief of Service, Neurology at Montefiore Einstein. She is the previous Chair of the North American Commission of the International League Against Epilepsy. Her research interests include: the temporal distribution of seizures, with emphasis on seizure clustering; seizure prediction and pre-emption; and alternative therapies for epilepsy. She is currently conducting electronic diary studies of seizure prediction and was the Principal Investigator of the first randomized controlled trial of stress management for refractory epilepsy using smartphone diaries. Dr. Haut has a Masters in Clinical Research Methods, and completed a K23 career development award from the NIH. She maintains an active adult epilepsy practice at Montefiore Medical Center, Moses Division.</p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Haut focuses on the special needs of epilepsy patients, such as pregnancy, stress, driving, work-related issues and issues in the elderly.

Research Focus

Dr. Haut's research is focused on seizure clustering; seizure prediction and pre-emption; and alternative therapies for epilepsy.

Elsevier Profile

Selected Publications

<ol>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><!-- [if !supportLists]--><span style="mso-bidi-font-size: 12.0pt; border: none windowtext 1.0pt; mso-border-alt: none windowtext 0in; padding: 0in;">Correa DJ, Labovitz DL, Milstein MJ, Monderer R, Haut SR. <strong><span style="font-weight: normal; mso-bidi-font-weight: bold;">Folding a neuroscience </span></strong></span><strong style="text-indent: -0.25in;"><span style="font-weight: normal; mso-bidi-font-weight: bold;">center into streamlined Covid-19 response teams: Lessons in origami. Neurology 2020, in press.</span></strong></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span lang="EN" style="text-indent: -0.25in;"><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;</span></span><span class="author" style="text-indent: -0.25in;"><span lang="EN">Galanopoulou, AS</span></span><span lang="EN" style="text-indent: -0.25in;">, <span class="author">Ferastraoaru, V</span>, <span class="author">Correa, DJ</span>, </span><span lang="EN" style="text-indent: -0.25in;">Cherian K, Duberstein S, Gursky J, Hanumanthu R, Hung C, Molinero I, Khodakivska O, Legatt AD, Patel P, Rosengard J, Rubens E, Sugrue W, Yozawitz E, Mehler M, Ballaban-Gil K, Haut SR, Mosh&eacute; SL, Boro A. </span><span lang="EN" style="text-indent: -0.25in;">&nbsp;<span class="articletitle">EEG findings in acutely ill patients investigated for SARS</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN" style="mso-bidi-font-size: 12.0pt; font-family: 'Cambria Math','serif'; mso-bidi-font-family: 'Cambria Math'; mso-ansi-language: EN;">‐</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN">CoV-2/COVID</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN" style="mso-bidi-font-size: 12.0pt; font-family: 'Cambria Math','serif'; mso-bidi-font-family: 'Cambria Math'; mso-ansi-language: EN;">‐</span></span><span class="articletitle" style="text-indent: -0.25in;"><span lang="EN">19: A small case series preliminary report</span></span><span lang="EN" style="text-indent: -0.25in;">. Epilepsia Open. <span class="pubyear">2020</span>; <span class="vol">5</span>: <span class="pagefirst">314</span>&ndash; <span class="pagelast">324</span>.&nbsp;</span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><a href="https://www.sciencedirect.com/science/article/pii/S0920121119303869#!">… class="text2"><span style="color: windowtext; text-decoration-line: none;">Chiang S,&nbsp;</span></span></a><a name="baut0015"></a>Haut SR.&nbsp;<a name="baut0020"></a>Ferastaoaru V,&nbsp;<a name="baut0025"></a>Rao VR,&nbsp;<a name="baut0030"></a>&nbsp;M,&nbsp;<a name="baut0035"></a>Theodore WH,&nbsp;<a href="https://www.sciencedirect.com/science/article/pii/S0920121119303869#!">… class="text2"><span style="color: windowtext; text-decoration-line: none;">Moss</span></span></a><a name="baut0040"></a>&nbsp;R,&nbsp;Goldenholz DM.&nbsp;<span class="title-text">Individualizing the definition of seizure clusters based on temporal clustering analysis. Epilepsy Res 2020;163:1-10.</span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><strong style="text-indent: -0.25in;"><span style="font-weight: normal;"><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;</span></span></strong><strong style="text-indent: -0.25in;"><span style="border: none windowtext 1.0pt; mso-border-alt: none windowtext 0in; padding: 0in; font-weight: normal; mso-bidi-font-weight: bold;">Privitera M, Haut SR, Lipton RB, McGinley J, Cornes S. Seizure Self-prediction in a Randomized Controlled Trial of Stress Management. Neurology 2019;93(22):e2021-e2031</span></strong><span style="text-indent: -0.25in; color: windowtext;">1.<span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span lang="EN" style="text-indent: -0.25in; color: windowtext;">Ferastraoaru V, Goldenholz DM, Chiang S, Moss R, Theodore WH, Haut SR. Characteristics of large patient-reported outcomes: Where can one million seizures get us? Epilepsia Open. 2018 Jul 4;3(3):364-373&nbsp;</span></p>
</li>
<li>
<p class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span style="text-indent: -0.25in; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp; </span><span lang="EN" style="text-indent: -0.25in;">Goldenholz DM, Goldenholz SR, Moss R, French J, Lowenstein D, Kuzniecky R, Haut S, Cristofaro S, Detyniecki K, Hixson J, Karoly P, Cook M, Strashny A, Theodore WH. Is seizure frequency variance a predictable quantity? Ann Clin Transl Neurol. 2018 Jan 9;5(2):201-207</span></p>
</li>
<li>
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .25in; text-indent: -.25in; mso-pagination: widow-orphan; mso-list: l0 level1 lfo1; tab-stops: list .25in;"><span style="text-indent: -0.25in; font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp; </span><span style="text-indent: -0.25in;">Haut SR, Lipton RB, Cornes S, Dwivedi AK, Wasson R, Cotton S, Strawn J, Privitera M. Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial. &nbsp;</span><span class="jrnl" style="text-indent: -0.25in;">Neurology</span><span style="text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">. 2018 Mar 13;90(11)</span></p>
<p style="margin-left: .25in; text-indent: -.25in; line-height: normal; mso-list: l0 level1 lfo1; tab-stops: list .25in;">&nbsp;</p>
<p class="MsoNormal" style="margin-left: 0.25in; text-indent: -0.25in; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
</li>
<li>Fisher RS, Cross JH, D&rsquo;Souza C, French JA, Haut SR, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshe SL, Peltola J, Roulet Perez E, Scheffer IE, Schulze-Bonhage A, Somerville E, Sperling M, Yacubian E, Zuberi SM. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia. 2017 Apr;58(4):531-542</li>
<li>Patel P, Ferastaoaru V, Gold D, Lipnick A, Jehle R, Haut SR. Clinical characterization of the pre-ictal state in the pediatric population: A caretaker&rsquo;s perspective. Epilepsy Behav. 2017 Apr 18;70(Pt A):193-197</li>
<li>Robbins MS, Haut SR, Lipton RB, Milstein MJ, Ocava LC, Ballaban-Gil K, Mosh&eacute; SL, Mehler MF. A dedicated scholarly research program in an adult and pediatric neurology residency program. Neurology. 2017 Apr 4;88(14):1366-1370</li>
<li>Haut SR, Seinfeld S, Pellock J. Benzodiazepine use in Seizure emergencies: A systematic review. Epilepsy Behav. 2016 Oct;63:109-117.</li>
<li>Ferastraoaru V, Schulze-Bonhage A, Lipton RB, D&uuml;mpelmann M, Legatt AD, Blumberg J,&nbsp; Haut SR. Termination of seizure clusters is related to the duration of focal seizures. Epilepsia &nbsp;2016 Mar 31.</li>
<li>Pillai J, Haut SR, Masur D. Orbitofrontal cortex dysfunction in Psychogenic Non-Epileptic Seizures. A proposal for a two-factor model. Med Hypotheses. 2015 Apr;84(4):363-9</li>
<li>Haut SR. Seizure Clusters: Characteristics and Treatment. Curr Opin Neurol. 2015 Apr;28(2):143-50</li>
<li>Lipton RB,BuseDC, Hall CB, Tennen H, DeFreitas TA, Borkowski TM, Haut SR. Reduction in Perceived Stress as a Migraine Trigger: Testing the &ldquo;Let-down Headache&rdquo; Hypothesis. Neurology 2014; Apr 22;82(16):1395-401</li>
<li>Privitera M, Walters M, Lee I, Polak E, Fleck A, Schwieterman D, Haut SR. Characteristics of People with Stress Precipitated Seizures. Epilepsy Behav 2014 Oct;41:74-77</li>
<li>Haut SR, Hall CB, Borkowski T, Tennen H, Lipton RB. Modeling seizure self-prediction: An e-diary study. Epilepsia 2013; Nov;54(11):1960-7.</li>
<li>Haut SR. Predicting seizures: Are we there yet? Epilepsy Currents 2013 Nov;13(6):276-8.</li>
<li>Haut SR, Hall CB, Borkowski T, Tennen H, Lipton RB. Clinical features of the pre-ictal state: Mood changes and premonitory symptoms. Epilepsy and Behavior 2012, 23:415-421.</li>
<li>Pillai J, Haut SR. Patients with epilepsy and psychogenic non-epileptic seizures: An inpatient video-EEG monitoring study. Seizure. 2012, 21(1):24-7.</li>
<li>Schulze-BonhageA, Haut SR. Premonitory features and seizure self-prediction: Artifact or real? Epilepsy Res 2011, 97(3);231-235.</li>
<li>Haut SR, Lipton RBL. Predicting Seizures: A Behavioral Approach. Neurol Clinics 2009, 27(4);925-940.</li>
<li>Haut SR. Psychiatric History and Temporal Lobectomy Outcome: Looking to the Past to Predict the Future. Epilepsy Currents 2009, 9(5):1-3</li>
<li>Haut SR, Katz M, Masur J, Lipton RBL. Seizures in the Elderly: Impact on Mental Status, Mood and Sleep. Epilepsy and Behavior 2009;14(3):540-544.</li>
<li>Hall CB, Lipton RB, Tennen H, Haut SR. Early Follow-up Data From Seizure Diaries Can Be Used To Predict Subsequent Seizures in Same Cohort By Borrowing Strength Across Participants. Epilepsy and Behavior 2009;14(3);472-475.</li>
<li>Bower CM, Hays RD, Devinsky O, Spencer SS, Sperling MR, Haut S, Vassar S, Vickrey BG. Expectations Prior to Epilepsy Surgery: An Exploratory Comparison of Men and Women. Seizure 2009;18(3):228-231</li>
<li>Brody BD and Haut SR. Ending the Doctor-Patient Relationship in Neurology Practice. The Neurologist 2009;15(5): 277-81.</li>
<li>Haut SR, Hall CD, Masur J, Lipton RB. Seizure Occurrence: Precipitants and Prediction. Neurology 2007;69 1905-1910.</li>
<li>Lado F, Spiegel R, Masur J, Boro A, Haut SR. Value of routine screening for bone demineralization in an urban population of patients with epilepsy. Epil Res 2007; 78(2-3);155-160</li>
<li>Chin PS, Berg AT, Spencer SS, Sperling MR, Haut S et al. Employment Outcomes Following Resective Epilepsy Surgery. Epilepsia 2007;Dec;48(12):2253-7.8.<span style="font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-size: 7.0pt; line-height: normal; font-variant: normal;">&nbsp; &nbsp;</span></li>
<li>Haut SR, Hall CD, LeValley A, Lipton RB. Can patients with epilepsy predict their seizures? Neurology, 2007; 68:262-266.</li>
<li>Spencer SS, Berg AT, Vickrey BG, Sperling MR, Bazil CW, Haut S, Langfitt JT, Walczak TS, Devinsky O; Multicenter Study of Epilepsy Surgery. Health-related quality of life over time since resective epilepsy surgery. Ann Neurol. 2007 Oct;62(4):327-34</li>
<li>Haut SR, Bigal M, Lipton RB. Chronic Disorders With Episodic Manifestations: Focus on Epilepsy and Migraine. Lancet Neurology 2006;5:148-157.&nbsp;</li>
</ol>

EMR ID

3969

Biography

<p>Dr. Sheryl Haut is Director of the Adult Epilepsy Program at Montefiore. She has extensive experience treating all forms of epilepsy in young and older adults, and in tailoring treatments to the individual. She focuses on special needs such as pregnancy, stress, driving, work related issues, and issues in the elderly.</p> <p>Dr. Haut has an extensive research background, including a Masters of Clinical Research with Distinction from Albert Einstein College of Medicine. Her research interests focus on seizure clustering; seizure prediction and pre-emption; and alternative therapies for epilepsy. She is one of the first investigators to run a clinical trial of stress management for epilepsy, using smartphone diaries.</p> <p>Dr. Haut is the current Chair of the North American Commission of the International League Against Epilepsy, and is active nationally in the American Epilepsy Society, and the American Academy of Neurology, serving on committees of both organizations. She has authored more than 50 papers/book chapters on epilepsy, and has been featured in Top Doctors of NY annually since 2009. She maintains an active adult epilepsy practice at the Moses Campus.</p>

Is Open Scheduling

Off

Jonathan M. Gursky

https://assets.montefioreeinstein.org/profiles/images/physphoto/Gursky_Jonathan_MD_420x504.jpg

First Name

Jonathan

Last Name

Gursky

NPI

1275950487

Faculty ID

16181

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Gursky focuses on the various needs of epilepsy patients including issues related to medication management and driving.

Research Focus

Dr. Gursky's research focuses on seizure triggers in addition to seizure prediction and analysis. He is involved in various clinical trials investigating new potential therapies for epilepsy.&nbsp;

Elsevier Profile

EMR ID

13408

Biography

<p>Jonathan M. Gursky, MD, is an Attending Physician at Montefiore and Assistant Professor of Neurology at our Albert Einstein College of Medicine. His clinical focus is on the diagnosis and treatment of adults and adolescents with epilepsy and seizure disorders.</p><p>After earning his Bachelor of Science at Cornell University in 2010, Dr. Gursky attended the New York University School of Medicine, where he received his Doctor of Medicine in 2014. He began his postgraduate training in 2014 with a year-long internship in internal medicine at Icahn School of Medicine at Mount Sinai. He continued his training at this institution and completed a residency in neurology in 2018, becoming Chief Resident in his final year. In 2019, Dr. Gursky completed a fellowship in clinical neurophysiology at Montefiore.</p><p>Expanding on his clinical focus, Dr. Gursky&rsquo;s research examines the interactions between epilepsy with various neurological and general medical disorders. His findings have been published in peer-reviewed journals and articles and have been shared at national lectures and presentations.</p><p>Dr. Gursky holds additional clinical interests in the effects of epilepsy on mental and behavioral health.</p><p>Dr. Gursky is a member of the American Academy of Neurology, the American Clinical Neurophysiology Society and the American Epilepsy Society and is board certified by the American Board of Psychiatry and Neurology. </p>

Is Open Scheduling

Off

Lauren Gluck

https://assets.montefioreeinstein.org/profiles/images/physphoto/Gluck_Lauren_MD_420x504.jpg

First Name

Lauren

Last Name

Gluck

NPI

1033524780

Faculty ID

16274

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>After receiving her medical degree from the University at Buffalo School of Medicine, Dr. Gluck completed her medicine internship and neurology residency at Montefiore Medical Center and then her neuroimmunology fellowship at Yale University. She specializes in the diagnosis and treatment of adult and adolescent multiple sclerosis, neuromyelitis optica, neurosarcoidosis, autoimmune encephalitis, and other inflammatory diseases that affect the central nervous system.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Diagnosis and treatment of adult and adolescent multiple sclerosis, neuromyelitis optica, neurosarcoidosis, autoimmune encephalitis, and other inflammatory diseases that affect the central nervous system

Research Focus

Clinical outcomes in multiple sclerosis

Elsevier Profile

EMR ID

29225

Biography

<p>Lauren Gluck, MD, is the Director of the Montefiore Multiple Sclerosis Center and Assistant Professor at our Albert Einstein College of Medicine. Her clinical focus is on neuroimmunological diseases that affect the brain and spinal cord, including adult and adolescent multiple sclerosis, neuromyelitis optica, neurosarcoidosis and autoimmune encephalitis.</p><p>In 2010, Dr. Gluck received her Bachelor of Science in biology and community health at Tufts University. She went on to University at Buffalo School of Medicine and Biomedical Sciences, earning her Doctor of Medicine in 2014. She completed her medicine internship and neurology residency at Montefiore Medical Center in 2018, followed by a clinical fellowship in neuroimmunology at Yale New Haven Hospital in 2019.</p><p>Dr. Gluck&rsquo;s research focus is on the clinical outcomes of multiple sclerosis as well as medical education. She has presented her work at several national and international meetings and has published original communications in many reviewed journals.</p><p>Dr. Gluck has received many recognitions, including the American Academy of Neurology Medical Student Prize for Excellence in Neurology in 2014, and becoming a Consortium of MS Centers Mentorship Forum Scholar in 2018. She is board certified in neurology and is a member of several professional organizations, including the American Medical Association, the American Academy of Neurology and the Federation of Clinical Immunology Societies.</p>

Is Open Scheduling

Off

Karen R. Ballaban-Gil

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/c22b4660-58cd-11ee-9065-d1774810abb1.jpg

First Name

Karen

Last Name

Ballaban-Gil

NPI

1508941816

Faculty ID

642

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Karen Ballaban-Gil is Professor of Neurology and Pediatrics, the Director of the Child Neurology Residency Training Program and Director of Outpatient Child Neurology Services at the Albert Einstein College of Medicine. She graduated Magna Cum Laude from Union College and Cum Laude from Albany Medical College, in the 6 year combined B.S- M.D. program. Dr. Ballaban-Gil trained in general pediatrics at The Johns Hopkins Hospital, and trained in child neurology and clinical neurophysiology and epilepsy at the Albert Einstein College of Medicine. She received board certifications in pediatrics, neurology with special competence in child neurology , clinical neurophysiology and in epilepsy.</p>
<p><br />Dr. Ballaban-Gil has a large clinical practice in child neurology, including the evaluation and treatment of children with epilepsy, headaches, sleep disorders, autism and other developmental disabilities. Her research interests include the relationship between epilepsy and language regression in youngsters with Landau-Kleffner Syndrome, autism, and other developmental disorders of higher cognitive functioning. In addition, she runs the Ketogenic Diet program for the management of intractable epilepsy at the Montefiore Medical Center - Comprehensive Epilepsy Center. Her publications include numerous papers on autism, epilepsy related language disorders, and the Ketogenic Diet.</p>
<p>&nbsp;</p>

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

3700

Biography

<p>Karen Ballaban-Gil, MD, is Director, Pediatric Epilepsy Center and Deputy Director, Division of Child Neurology at the Children&rsquo;s Hospital at Montefiore Einstein, and Professor, Pediatrics and Neurology at our Albert Einstein College of Medicine. Dr. Ballaban-Gil has a large clinical practice in child neurology, including the evaluation and treatment of children with epilepsy, headaches, sleep disorders, autism and other developmental disabilities.</p><p>After receiving her Bachelor of Science at Union College in 1984, Dr. Ballaban-Gil earned her Doctor of Medicine in 1986 at the Albany Medical College. She began her postgraduate training at Johns Hopkins Hospital, completing two years as an intern and assistant resident in pediatrics before coming to Einstein, where she completed a residency in child neurology, followed by a fellowship in epilepsy and electrophysiology in 1991.</p><p>Dr. Ballaban-Gil&rsquo;s research interests include the relationship between epilepsy and language regression in youngsters with Landau-Kleffner Syndrome, autism and other developmental disorders of higher cognitive functioning. Her publications include numerous papers on autism, epilepsy related language disorders and the Ketogenic Diet. She has shared her work through national and international meetings, and has been a peer reviewer for a variety of medical journals, including <em>Epilepsia</em> and <em>Cephalgia</em>.</p><p>Dr. Ballaban-Gil is board certified by the American Board of Psychiatry and Neurology in Neurology with special competence in Child Neurology and with Certification in Epilepsy.</p>

Is Open Scheduling

Off

Howard Geyer

https://assets.montefioreeinstein.org/profiles/images/10183-howard geyer.jpg

First Name

Howard

Last Name

Geyer

NPI

1235298688

Faculty ID

10183

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Howard Geyer is Director, Division of Movement Disorders, Montefiore, and Assistant Professor, Neurology, Albert Einstein College of Medicine.&nbsp;He received his MD and PhD degrees from the University of Pennsylvania.&nbsp;He was chief resident in Neurology at Montefiore, where he also completed a fellowship in Clinical Neurophysiology.&nbsp;He completed an additional fellowship in Movement Disorders at Beth Israel Medical Center.&nbsp;Dr. Geyer regularly lectures and contributes to book chapters and journal articles on a variety of neurologic topics.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4312

Is Open Scheduling

Off

Aristea S. Galanopoulou

https://assets.montefioreeinstein.org/profiles/images/physphoto/Galanopoulou_Aristea_MD_420x504.jpg

First Name

Aristea

Last Name

Galanopoulou

NPI

1891870580

Faculty ID

6874

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>The maturation of GABA_A<span class="apple-converted-space">&nbsp;</span>receptor-mediated signaling from depolarizing to inhibitory is an age-related process controlled by cation chloride cotransporters, such as KCC2. As a result, GABA exerts dual functions, being an important neurotrophic factor during early development and the principal inhibitory neurotransmitter of the mature central nervous system. In our laboratory we have been investigating the age mechanisms through which early life stressors and seizures may disrupt the normal patterns of brain development, by disrupting the neurotrophic effects of GABA. We are also studying methods to reverse these adverse processes. Furthermore, we are very interested in understanding how epileptogenesis proceeds in the developing brain and what is the specific role of GABA_A<span class="apple-converted-space">&nbsp;</span>receptors in this process.</p>
<p>To better understand the pathophysiology and design better methods to treat catastrophic early life epilepsies, we are developing and studying new models of early life epilepsy. These include models of symptomatic infantile spasms that recapitulate most of the features of the human condition. Several projects are under way to (a) elucidate the pathophysiology of infantile spasms, and (b) conduct preclinical trials to find better treatments for spasms and the associated comorbidities. Our studies have provided preclinical evidence for new potential treatments with disease modifying properties for these early life epileptic encephalopathies, such as mTOR inhibitor, carisbamate and a new vigabatrin analog.</p>
<p>Post-traumatic epilepsy is a common consequence of traumatic brain injury leading to high morbidity and morbidity. Our lab is participating in an international multicenter preclinical consortium, EpiBioS4Rx, leading efforts to develop better therapies for post-traumatic epilepsy. We use a rodent model of traumatic brain injury to identify targets and test for better therapies, through a combination of expression studies, in vivo behavioral and electrophysiologic monitoring and therapy screening to identify antiepileptogenic compounds. Furthermore, through a separate project, we are looking into factors predicting epilepsy and behavioral outcomes after traumatic brain injury.</p>
<p>Genetic etiologies are often identified in patients with epilepsies. Our lab has been investigating genes involved in lissencephaly associated epilepsies and developmental disorders as well as Rett syndrome which is due to MeCP2 gene mutations. Through the use of mouse models we have been investigating genotype-phenotype correlations and mechanisms involved with the ultimate goal of testing therapies.</p>
<p>Students interested in these projects will gain exposure to a variety of<span class="apple-converted-space">&nbsp;</span><em>in vivo</em><span class="apple-converted-space">&nbsp;</span>and<span class="apple-converted-space">&nbsp;</span><em>in vitro</em><span class="apple-converted-space">&nbsp;</span>techniques that combine molecular biology<em>, in vivo</em><span class="apple-converted-space">&nbsp;</span>and<span class="apple-converted-space">&nbsp;</span><em>in vitro</em><span class="apple-converted-space">&nbsp;</span>electrophysiology, histological, and behavioral studies and will be involved in projects with direct translational relevance to the clinical practice, i.e. identification of novel therapies.&nbsp;</p>
<p>&nbsp;</p>
<p><!--EndFragment--></p>

Research Areas

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Adult epileptology, clinical neurophysiology

Research Focus

Post-traumatic epilepsy, developmental and epileptic encephalopathies, infantile spasms, GABA receptors, biomarkers, treatments for epilepsies

Elsevier Profile

Selected Publications

<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">1.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS: &ldquo;Dissociated gender-specific effects of recurrent seizures on GABA signaling in CA1 pyramidal neurons: role of GABA_A&nbsp;receptors&rdquo;: J Neurosci 28 (7): 1557-67 (2008). PMID 18272677. https://www.jneurosci.org/content/28/7/1557.long</span></p&gt;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">2.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Briggs SW, Mowrey W, Hall CB,<strong>&nbsp;</strong>Galanopoulou AS<strong>.&nbsp;</strong>CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms. Epilepsia (2014) 55(1):94-102. PMID 24321005.&nbsp;https://onlinelibrary.wiley.com/doi/full/10.1111/epi.12424&nbsp;</span>…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">3.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS&nbsp;and Mosh&eacute; SL. Pathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: a view from preclinical studies. Neurobiology of Disease (2015): Neurobiol Dis. 2015 Jul;79:135-49. PMID 25968935.&nbsp;&nbsp;https://www.sciencedirect.com/science/article/pii/S096999611500162X?via…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">4.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS, Mowrey WB, Liu W, Li Q, Shandra O, Moshe SL.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Preclinical Screening for Treatments for Infantile Spasms in the Multiple Hit Rat Model of Infantile Spasms: An Update. Neurochem Res. 2017;42:1949-61.&nbsp;PMID 28462453.&nbsp;&nbsp;https://link.springer.com/article/10.1007%2Fs11064-017-2282-0</span></p…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">5.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Galanopoulou AS, French JA, O&rsquo;Brien T, Simonato M. &ldquo;Harmonization in preclinical epilepsy research: a joint AES/ILAE translational initiative&rdquo;. Epilepsia (2017) 58 (Suppl 4):7-9. PMID 29105072. https://onlinelibrary.wiley.com/doi/full/10.1111/epi.13921</span></p&gt;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">6.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Ono T, Wagenaar J, Giorgi FS et al, Galanopoulou AS. A companion to the preclinical common data elements and case report forms for rodent EEG studies. A report of the TASK3 EEG Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2018;3:90-103. PMID 30450486. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6210053/pdf/EPI4-3-90.pdf<…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">7.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Akman O, Raol YH, Auvin S et al, Galanopoulou AS.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Methodologic recommendations and possible interpretations of video-EEG recordings in immature&nbsp;rodents used as experimental controls: A&nbsp;TASK1-WG2 report of the ILAE/AES Joint Translational&nbsp;Task Force. Epilepsia Open. (2018)&nbsp;vol 3: 437-459. PMID 30525114. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276777/pdf/EPI4-3-437.pdf…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">8.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Katsarou AM, Li, Q, Liu W, Mosh&eacute; SL, Galanopoulou AS.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">&ldquo;Acquired parvalbumin-selective interneuronopathy in the multiple-hit model of infantile spasms: a putative basis for the partial responsiveness to vigabatrin analogs?&rdquo; Epilepsia Open (2018) vol 3 (S2): 155-164. PMID 30564774. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293059/pdf/EPI4-3-155.pdf…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">9.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Salar S, Moshe SL, Galanopoulou AS. Metabolic etiologies in West syndrome.&nbsp;</span><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Epilepsia Open. 2018;3:134-66.</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;"><a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/29881795"><span lang="PT-BR">https://www.ncbi.nlm.nih.gov/pubmed/29881795</span></a></span></p&gt;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">10.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Saletti PG, Ali I, Casillas-Espinosa PM et al, Galanopoulou AS.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">In search of antiepileptogenic treatments for post-traumatic epilepsy. Neurobiol Dis. (2019)&nbsp;123: 86-99 (2019).&nbsp; PMID: 29936231.&nbsp;<a style="color: #954f72; text-decoration: underline;" href="https://www.sciencedirect.com/science/article/pii/S0969996118301980?via…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">11.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Galanopoulou AS, Ferastraoaru V, Correa DJ, Cherian K, Duberstein S, Gursky J, Hanumanthu R, Hung C, Molinero I, Khodakivska O, Legatt AD, Patel P, Rosengard J, Rubens E, Sugrue W, Yozawitz E, Mehler MF, Ballaban-Gil K, Haut SR, Moshe SL, Boro A. EEG findings in acutely ill patients investigated for SARS-CoV-2/COVID-19: A small case series preliminary report. Epilepsia Open. 2020;5:314-24.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/32537529">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">12.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif;">Parihar R, Ferastraoaru V, Galanopoulou AS, Geyer HL, Kaufman DM.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Outcome of Hospitalized Parkinson's Disease Patients with and without COVID-19. Mov Disord Clin Pract. 2021;8:859-67.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/34226870">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">13.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Akman O, Briggs SW, Mowrey WB, Moshe SL, Galanopoulou AS. Antiepileptogenic effects of rapamycin in a model of infantile spasms due to structural lesions. Epilepsia. 2021;62:1985-99.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/34212374">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">14.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Galanopoulou AS, Loscher W, Lubbers L, O'Brien TJ, Staley K, Vezzani A, D'Ambrosio R, White HS, Sontheimer H, Wolf JA, Twyman R, Whittemore V, Wilcox KS, Klein B. Antiepileptogenesis and disease modification: Progress, challenges, and the path forward-Report of the Preclinical Working Group of the 2018 NINDS-sponsored antiepileptogenesis and disease modification workshop. Epilepsia Open. 2021;6:276-96.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/34033232">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">15.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Katsarou AM, Kubova H, Auvin S, Mantegazza M, Barker-Haliski M, Galanopoulou AS, Reid CA, Semple BD.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">A companion to the preclinical common data elements for rodent models of pediatric acquired epilepsy: A report of the TASK3-WG1B, Pediatric and Genetic Models Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2022.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/35950641">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">16.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Medel-Matus JS, Lagishetty V, Santana-Gomez C, Shin D, Mowrey W, Staba RJ, Galanopoulou AS, Sankar R, Jacobs JP, Mazarati AM. Susceptibility to epilepsy after traumatic brain injury is associated with preexistent gut microbiome profile. Epilepsia. 2022;63:1835-48.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/35366338">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">17.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Saletti PG, Mowrey WB, Liu W, Li Q, McCullough J, Aniceto R, Lin IH, Eklund M, Casillas-Espinosa PM, Ali I, Santana-Gomez C, Coles L, Shultz SR, Jones N, Staba R, O'Brien TJ, Moshe SL, Agoston DV, Galanopoulou AS, EpiBio SRSG. Early preclinical plasma protein biomarkers of brain trauma are influenced by early seizures and levetiracetam. Epilepsia Open. 2023;8:586-608.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37026764">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">18.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Coles L, Forcelli PA, Leclercq K, Katsarou AM, Klein BD, Potschka H, Koehling R, Harte-Hargrove L, Galanopoulou AS, Metcalf CS. Preclinical common data elements for general pharmacological studies (pharmacokinetic sample collection, tolerability, and drug administration). A report of the TASK3-WG1A General Pharmacology Working Group of the ILAE/AES Joint Translational Task Force. Epilepsia Open. 2023.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/36896626">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">19.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Guerrini R, Conti V, Mantegazza M, Balestrini S, Galanopoulou AS, Benfenati F. Developmental and epileptic encephalopathies: from genetic heterogeneity to phenotypic continuum. Physiol Rev. 2023;103:433-513.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/35951482">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">20.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Auvin S, Galanopoulou AS, Moshe SL, Potschka H, Rocha L, Walker MC. Revisiting the concept of drug-resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force. Epilepsia. 2023;64:2891-908.&nbsp;<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37676719">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">21.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Grandizoli Saletti P, Casillas-Espinosa PM, Panagiotis Lisgaras C, Bi Mowrey W, Li Q, Liu W, Brady RD, Ali I, Silva J, Yamakawa G, Hudson M, Li C, Braine EL, Coles L, Cloyd JC, Jones NC, Shultz SR, Moshe SL, O'Brien TJ, Galanopoulou AS. Tau Phosphorylation Patterns in the Rat Cerebral Cortex After Traumatic Brain Injury and Sodium Selenate Effects: An Epibios4rx Project 2 Study. J Neurotrauma. 2024;41:222-43.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/36950806">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">22.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif;">Lucasius C, Grigorovsky V, Nariai H, Galanopoulou AS, Gursky J, Moshe SL, Bardakjian BL. Biomimetic Deep Learning Networks With Applications to Epileptic Spasms and Seizure Prediction. IEEE Trans Biomed Eng. 2024;71:1056-67.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37851549">https://www.ncbi.nlm.nih…;
<p class="EndNoteBibliography" style="margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; mso-no-proof: yes;"><span style="mso-list: Ignore;">23.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif;">Samfira IMA, Galanopoulou AS, Nariai H, Gursky JM, Moshe SL, Bardakjian BL.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif;">EEG-based spatiotemporal dynamics of fast ripple networks and hubs in infantile epileptic spasms. Epilepsia Open. 2024;9:122-37.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/37743321">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">24.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Perucca E, French JA, Aljandeel G, Balestrini S, Braga P, Burneo JG, Felli AC, Cross JH, Galanopoulou AS, Jain S, Jiang Y, Kalviainen R, Lim SH, Meador KJ, Mogal Z, Nabbout R, Sofia F, Somerville E, Sperling MR, Triki C, Trinka E, Walker MC, Wiebe S, Wilmshurst JM, Wirrell E, Yacubian EM, Kapur J. Which terms should be used to describe medications used in the treatment of seizure disorders? An ILAE position paper. Epilepsia. 2024;65:533-41.<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/38279786">https://www.ncbi.nlm.nih…;
<p class="MsoNormal" style="mso-margin-top-alt: auto; mso-margin-bottom-alt: auto; margin-left: .5in; text-indent: -.25in; mso-list: l0 level1 lfo1; tab-stops: list .5in; background: white;"><!-- [if !supportLists]--><span style="font-size: 9.0pt; font-family: 'Verdana',sans-serif; mso-fareast-font-family: Verdana; mso-bidi-font-family: Verdana; color: black; mso-color-alt: windowtext; mso-font-kerning: 0pt; mso-ligatures: none;"><span style="mso-list: Ignore;">25.<span style="font: 7.0pt 'Times New Roman';">&nbsp;&nbsp;</span></span></span><!--[endif]--><span lang="PT-BR" style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Pease M, Gupta K, Moshe SL, Correa DJ, Galanopoulou AS, Okonkwo DO, Gonzalez-Martinez J, Shutter L, Diaz-Arrastia R, Castellano JF.&nbsp;</span><span style="font-size: 9pt; font-family: Verdana, sans-serif; color: black;">Insights into epileptogenesis from post-traumatic epilepsy. Nat Rev Neurol. 2024;20:298-312.&nbsp;<a style="color: #954f72; text-decoration: underline;" href="https://www.ncbi.nlm.nih.gov/pubmed/38570704">https://www.ncbi.nlm.nih…;
<p></p>
<p class="MsoNormal" style="font-size: medium;"><span style="font-size: 9pt; font-family: Verdana, sans-serif;">&nbsp;</span></p>

EMR ID

4043

Is Open Scheduling

Off

Victor Ferastraoaru

https://assets.montefioreeinstein.org/profiles/images/physphoto/Ferastraoaru_Victor_MD_420x504.jpg

First Name

Victor

Last Name

Ferastraoaru

NPI

1851689798

Faculty ID

14637

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

54052

Is Open Scheduling

On

Ali Ezzati

https://assets.montefioreeinstein.org/profiles/images/Ezzati_Ali_MD_420x504.jpg

First Name

Ali

Last Name

Ezzati

NPI

1649617333

Faculty ID

13307

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Ezzati is an Assistant Professor in the Department of Neurology at the Albert Einstein College of Medicine and Montefiore Medical Center. His research interest is in epidemiology, clinical trial design and development of digital health technology.&nbsp; Dr. Ezzati is the recipient of Alzheimer&rsquo;s Association Clinician Scientist Fellowship (AACSF) award.&nbsp; In his research, Dr. Ezzati uses big-data from cohorts and clinical trials, and apply advanced statistical methods and Machine Learning techniques to develop predictive and diagnostic tools to improve prognosis prediction and make early diagnosis more accurate for chronic Neurological diseases such as dementia.&nbsp;&nbsp;</p>
<p>&nbsp;</p>
<p>For a complete list of publications please see Dr. Ezzati's&nbsp;<a href="https://nam02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fschol…; target="new">Google Scholar page</a>.&nbsp; &nbsp;</p>

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

56331

Is Open Scheduling

Off